students on campus



Profile for Barry Maurer, MD

Barry Maurer

Barry Maurer, MD

  • Committee Member IACUC, Institutional Animal Care and USe Committee, Institutional Animal Care and Use Committee
  • Equipment Committee , Cell and Molecular Biology Department
  • Committee Member, Commercialization Grant Review, Office of Technology Commercialization
  • Intellectual Property Committee, Commercial Development Grant Review Subcommittee, Member
  • Steering Committee Member
  • Chief Medical Officer
  • SPOC Advisory Committee Member, CBB Dept
  • Member, Intellectual Property Review Committee
  • Committee Member. TTUHSC Cell and Molecular Biology Graduate Program
  • SPOC Scientific Advisory Board
  • Cancer Center Program Committee
  • CMB Program Committee Member
  • Member, Department of Internal Medicine, Division of Biomedical Research
  • Associate Professor - Cell Biology, Pediatrics, and Internal Medicine (Tenured)
Mail Address: 3601 4th St Stop 9445
Lubbock TX 79430-9445

Positions:

  • Committee Member IACUC, Institutional Animal Care and USe Committee, Institutional Animal Care and Use Committee , Texas Tech University Health Sciences Center Lubbock, TX 2011-Present
  • Equipment Committee , Cell and Molecular Biology Department, Texas Tech University Health Sciences Center Lubbock, TX 2011-Present
  • Committee Member, Commercialization Grant Review, Office of Technology Commercialization, Texas Tech University Health Sciences Center Lubbock, TX 2010-Present
  • Intellectual Property Committee, Commercial Development Grant Review Subcommittee, Member, Texas Tech University Health Sciences Center Lubbock, TX 2010-Present
  • Steering Committee Member , TTU Cancer Institute Lubbock, TX 2010-Present

Post Doctoral Education:

  • Research Fellowship: Childrens Hospital Los Angeles (CA) Research Institute, 2000
  • Clinical Fellowship: Fred Hutchison Cancer Research Center, 1997
  • Residency: LAC/USC Pediatric Pavilion, 1993
  • Internship: Children’s Hospital of Michign, Detroit MI, PGY 1, 1991

Education:

  • MD: Wayne State University, 1990
  • PhD: California Institute of Technology, 1990
  • B.S., B.S.E.: University of Michigan, 1980
  • High School Diploma: Notre Dame High School, 1976

Selected Publications:

  • Song MM, Makena MR, Hindle A, Koneru B, Thinh H Nguyen , Verlekar DU, Cho H, Maurer BJ, Kang MH, Reynolds CP. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anti-cancer Drugs 2019;30(2):117-127.
  • Cho HE, Maurer BJ, Reynolds CP, Kang MH. Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Journal of Chromotography B-analytical Technologis in the Biomedical and Life Sciences 2019;1112:16-23.
  • Vad N, Wang D, Cho H, Verlekar D, Linch C, Reynolds CP, Kang MH, Maurer BJ. Dihydroceramide increase precedes golgi dispersal, pro-survival autophagy, ER stress, and UPR in fenretinide plus safingol treated neuroblastoma cells. Cancer Res 2018;78(13).
  • Vad NM, Maurer BJ. Abstract - Co-treatment with fenretinide and safingol induced p38 MAPK and/or FOXO3a activated pro-survival autophagy in glioblastoma multiforme cells.. Am Assoc Cancer Res (AACR) Annual Meeting 2017 2017;:#6383.
  • Vad NM, Maurer BJ. Abstract - ER stress, unfolded protein response, and autophagy are pro-survival responses to fenretinide + safingol treatment in GBM cells.. Am Assoc Cancer Res (AACR) Annual Meeting 2016 2016;:#16-A-6058-AACR.
  • Song MM, Makena MR, Maurer BJ, Kang MH, Reynolds CP. Abstract - Comparison of the cytotoxicity and increase of reactive oxygen species and dihydroceramides of fenretinide to its major metabolites (4-oxo- and 4-methoxyphenyl fenretinide) in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines.. Am Assoc Cancer Res (AACR) Annual Meeting 2015 2015;:#7049.
  • Reynolds CP, Maurer BJ. Use of Fenretinide to increase cytotoxic dihydroceramides a a novel cancer chemotherapeutic approach.. 2015.
  • Maurer BJ, Glade-Bender J, Kang MH, Matthay KK, Katzenstein H, Weiss W, Granger M, Czarnecki S, Reynolds CP. Abstract - Fenretinide (4-HPR)/Lym-X-Sorb™(LXS) Oral Powder + Ketoconazole in Patients with High- Risk (HR) Recurrent or Resistant Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial. J Clin Oncol 2014;:#10071.
  • Lopez-Barcons L , Maurer BJ, Reynolds CP . Abstract - Temozolomide + irinotecan followed by fenretinide/LXS + ketoconazole + vincristine is active in post-progrressive disease neuroblastoma zenografts.. Advacnes in Neuroblastoma (ANR) Congress 2014;May 13-16, 2014(Abstract A-0145).
  • Marachelian A, Kang MH, Glade-Bende J, Villablance J, Matthay KK, Reynolds CP, Maurer BJ. Abstract - Treatment with Fenretinide (4-HPR)/Lym-X-Sorb™(LXS) Oral Powder With Ketoconazole Increased Plasma levels and had Anti-tumor Activity in Patients with High-Risk (HR) Recurrent or Resistant Neuroblastoma (NB): A NANT Study. Advances in Neuroblastoma Research (ANR) 2014 Congress 2014;:A-0278.
  • Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.. BMC research notes 2014;7:256.
  • Vad N M , Wang D , Maurer BJ. Abstract - Molecular inhibition of autophagy enhances dihydroceramides-induced cell death in Glioblastoma Multiforme cell lines. Am Assoc Cancer Res (AACR) Annual Meeting 2013 2013;Abstract #6816.
  • Maurer BJ. Abstract - Treatment with Fenretinide (4-HPR)/ Lym-X-Sorb Oral Powder With Ketoconazole Increased Plasma Levels and had Anti-tumor Activity in Neuroblastoma Patients with High Risk (HR) Recurrent or Resistant Neuroblastoma. Advances in Neuroblastoma, ANR, 2014 Congress, Colonge, DE 2013;May 13-16, 2014(Abstract A-0278).
  • Holliday Jr MW, Cox SB, Kang MH, Maurer BJ. C22:0- and C24:0-dihydroceramides confer cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLos One 2013;8(9) e74768(doi:10.1371/hjournal.pone.0074768(2013)).
  • Shibina A , Seidel D , Somanchi SS , Lee DA , Stermann A , Maurer BJ, Lode HN , Reynolds CP , Huebener N . Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl). 2013;91:459-472.

Selected Presentations:

  • Vad N, Wang D, Cho , Hwangeui , Verlekar D, Linch C, Reynolds CP, Kang MH, Maurer BJ., Abstract, Annual Meeting, American Association for Cancer Research (AACR), 2018.
    Dihydroceramide increase precedes golgi dispersal, pro-survival autophagy, ER stress, and UPR in fenretinide + safingol treated neuroblastoma cells.
  • Vad N, Maurer BJ., Abstract, Annual Meeting, American Association for Cancer Research (AACR), 2017.
    Co-treatment with fenretinide and safingol induced p38 MAPK and/or FOXO3a activated pro-survival autophagy in glioblastoma multiforme cells.
  • Vad N, Wang D, Cho , Hwangeui , Verlekar D, Linch C, Reynolds CP, Kang MH, Maurer BJ., Abstract, Annual Conference, Cancer Prevention Research Institute of Texas (CPRIT), November 2017.
    Dihydroceramide increase precedes golgi dispersal, pro-survival autophagy, ER stress, and UPR in fenretinide + safingol treated neuroblastoma cells.
  • Maurer BJ., Annual Meeting, Cancer Prevention and Research Institute of Texas (CPRIT), November 2017.
    Translational investigations of fenretinide in childhood cancer.
  • Maurer BJ., Drug Discovery and Development Mini-Symposium, Texas Tech University Health Sciences Center, Lubbock, Texas December 2015.
  • Maurer BJ., Annual Meeting, Cancer Prevention and Research Institute of Texas (CPRIT), November 2015.
  • Maurer BJ., Annual Meeting of NANT Consortium Investigators, Redondo Beach, California 2014.
    NANT Protocol 2004-04
  • Maurer BJ., Hematology/Oncology Grand Rounds, University of Cincinnati , Cincinnati March 2014.

Selected Contracts and Grants:

  • Cancer Prevention Research Inst Texas (CPRIT), CPRIT RP150416
    2015-2019
    Translational Investigations on Fenretinide and Safingol for Pediatric Cancer Use
    $1,999,415.00 [Total Cost]
    Principal Investigator
  • NIH/NCI SBIR, NIH NCI R44 CA183316
    2014-2019
    A Phase I trial combining IV fenretinide and IV safingol to target overproduction of cytotoxic dihydroceramides in malignant cell.
    $1,100,000.00 [Total Cost]
    Co-Investigator
  • Cancer Prevention Research Inst Texas (CPRIT), CPRIT CP120090
    2014-2017
    A Phase IIa trial of IV fenretinide in Relapsed Peripheral T-cell Lymphoma (PTCL).
    $6,000,000.00 [Total Cost]
    Co-Investigator
  • NIH/NCI R21, CA161889-01
    2012-2016
    “A Phase I trial combining intravenous fenretinide and safingol to target overproduction of cytotoxic dihydroceramides in malignant cells”
    $430,000.00 [Total Cost]
    Principal Investigator
  • Cancer Prevention Research Inst Texas (CPRIT), CPRIT RP121060
    2012-2015
    Manufacture, Formulation, and IND-directed Toxicology of the Multifunctional Ceramide Catabolism Inhibitor D-threo-PPMP to enable Phase I Clinical Trials.
    $1,000,000.00 [Total Cost]
    Principal Investigator
  • The EVAN Foudation
    2013-2014
    "Manufacture and clinical testing of fenretinide/LXS oral powder in pediatric neuroblastoma in combination with ketoconazole and vincristine - SPOC, South Plains Oncology Consortium, Trial"
    $30,000.00 [Total Cost]
    Principal Investigator
  • NIH/NCI R15 , CA159298-01
    2012-2014
    “Novel L-threo-sphinanines for ceramides-based cancer therapy.”
    $249,000.00 [Total Cost]
    Principal Investigator
  • Cancer Prevention Research Inst Texas (CPRIT)
    2010-2014
    “Enhancing the anti-neuroblastoma activity of fenretinide by identifying and targeting sphingolipid pathways that confer resistance.”
    $0.00 [Total Cost]
    Co-Investigator
  • Private
    2001-2013
    Tyler’s Team Leukemia Fund Research Award
    $105,500.00 [Total Cost]
    Principal Investigator
  • Wilson Foundation
    2010-2012
    Preclinical Studies of Fenretinide/LXS Oral Powder in Mouse Xenograft Models of Ovarian Cancer in Support of Phase I/II Clinical Trials
    $0.00 [Total Cost]
    Principal Investigator

Selected Awards:

  • 1974-1978 National Merit Scholarship, .
  • 1980-1986 NIH NRSA Predoctoral Traineeship, .
  • 1990 M.D. Distinction in Biomedical Research, .
  • 2004 Eurand Award Grand Prize, Novel Approaches in Oral Drug Delivery; Controlled Release Society, 31st Annual Meeting 2004; For novel LXS oral fenretinide formulation., .
  • Block Teaching Award for GPMSD, Department of Medical Education (DoME), Texas Tech University Health Sciences Center, School of Medicine, 2017.

Selected Scheduled Teaching:

  • MSCI6107 General Principles, Multisystem Disorders and Cancer - Fall 2018
  • MSCI6107 General Principles, Multisystem Disorders and Cancer - Fall 2017
  • Therapy of Anemia - Fall 2016
  • GBTC5340 Biology of Cancer - Spring 2016
  • Therapy of Anemia - Fall 2015

Selected Directed Student Learning:

  • PhD Graduate Student Thesis Committee 2018 - Present
  • Dissertation Committee Member 2014 - Present
  • Dissertation Defense Committee Member 2014 - Present
  • Dissertation Committee Member 2013 - Present
  • Dissertation Committee Member 2012 - Present

Selected Non-Credit Instruction Taught:

  • Small Group Conferences - Texas Tech University Health Sciences Center, Weekly Cancer Center Laboratory Meeting, 2015 - Present
  • Lectures - Tyler’s Team Leukemia Fund, San Marino High School , “Advances in ALL Leukemia”, Speaker and Award Receipient, 2001 - Present
  • Continuing Education - Texas Tech University Health Sciences Center, Maintenance of Medical Licensure (MOC), 2016
  • Lectures - CureCancer Foundation, Fund Raising Event , October 2011 - October 2011
  • Lectures - Texas Tech University Health Sciences Center, 2011 Annual Cancer Symposium - Amarillo, April 2011 - April 2011
Research Interests

Developmental Therapeutics of new cancer agents and combinations; modulation of sphingolipid pathways as relates to therapeutic cancer applications; new cancer drug formulations

Teaching Interests

Cancer Cell Biology and Therapeutics; Topics in Pediatric Cancer and Pediatric Hematology

Clinical Interests

Phase I and 2 cancer trials in pediatric and adult oncology

Date last updated: 10/14/2019